Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic
Time: 8:45 am
day: Day One
• What is the best neoantigen prediction platform?
• What is the most robust approach to identifying the “right” neoantigen?
• How to best deliver a neoantigen therapy, vaccine or cell therapy?
• What type of vaccine, cell based, virus, RNA, DNA, peptide?
• Which approach is safer and more efficacious?
• Should the focus be on shared neoantigens or private neoantigens?